The FDA warned users of tirzepatid (Mounjaro, Zepbound) never to share KwikPens due to the risk of blood-borne pathogens, as noted in the updated label.[1] GLP-1 weight loss drugs account for more than 7% of all prescriptions in this category. The nurse was charged in connection with the distribution of fake GLP-1 drugs. The dosage of Afrezza has been revised. Tirzepatid is the active substance in Mounjaro for the treatment of type 2 diabetes and in Zepbound for the chronic weight management of obese (BMI ≥ 30 kg/m²) or overweight (BMI ≥ 27 kg/m²) adults with comorbidities. The FDA has announced that the shortage of tirzepatide has been resolved, banning compounded versions; state pharmacies must cease by February 18, 2025, and outsourcing facilities by March 19, 2025.[1][4][5][7] The FDA has issued warnings about the safety risks of compounded GLP-1 drugs, including contamination and improper dosing.[7]